The Novel Oral mTORC1/2 Inhibitor TAK-228 Reverses Trastuzumab Resistance in HER2-Positive Breast Cancer Models

The Novel Oral mTORC1/2 Inhibitor TAK-228 Reverses Trastuzumab Resistance in HER2-Positive Breast Cancer Models

The use of anti-HER2 therapies has significantly improved clinical outcome in patients with HER2-positive breast cancer, yet a substantial proportion of patients acquire resistance after a period of treatment. The PI3K/AKT/mTOR pathway is a good target for drug development, due to its involvement in...

Full description

Bibliographic Details
Main Authors: Marta Sanz-Álvarez, Ester Martín-Aparicio, Melani Luque, Sandra Zazo, Javier Martínez-Useros, Pilar Eroles, Ana Rovira, Joan Albanell, Juan Madoz-Gúrpide, Federico Rojo
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Cancers
Subjects:
breast cancer
resistance
anti-receptor therapy
trastuzumab
PI3K
mTOR
Online Access:https://www.mdpi.com/2072-6694/13/11/2778

Internet

https://www.mdpi.com/2072-6694/13/11/2778

Similar Items